KU-55933 (ATM Kinase Inhibitor)

製品コードS1092

KU-55933 (ATM Kinase Inhibitor)化学構造

分子量(MW):395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

サイズ 価格(税別)  
JPY 18592.00
JPY 11620.00
JPY 19920.00
JPY 61420.00

文献中Selleckの製品使用例(41)

カスタマーフィードバック(4)

  •  

    Effects of NVP-BKM120 and KU-55933 and their combination on the DNA damage response. A, HCC1937 cells were treated for 18 hours with NVP-BKM120 at 2.5 μmol/L, KU-55933 at 10 μmol/L, or their combination, subjected to ionizing radiation(IR) with 10 Gy or mock, lysed 6 hours later, and subjected to immunoblotting with antibodies as indicated.

    Cancer Discov 2012 2, 1048-1063. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    Confocal immunostaining (left panel) graphical representation (right panel) for phosphorylation of S25-53BP1, which is known to be ATM dependent, at different time points following irradiation of HEK 293T parental and p18CycE-expressing cells in the absence or presence of the ATM inhibitor, KU55933. Error bars represent SD (n=3).

    Nucleic Acids Res 2011 41, 10157-69. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

  •  

    59PDb2 repression is restored in c22 by inhibition of DNAPKcs. Shown are representative ChIP QPCR of USF-1 binding at Db2 (A) and Db2 mRNA levels (B) in P5424-c22 1 d after treatment with the indicated kinase inhibitors.

    J Immunol 2012 188, 2266-2275. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    effect of ATM inhibitor in etoposide-induced cell death. The cells were pretreated with KU55933 (2 μM) for 1 h before etoposide treatment.

     

     

    J Biol Chem 2011 286, 8394-8404. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

製品安全説明書

ATM/ATR阻害剤の選択性比較

生物活性

製品説明 KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
ターゲット
ATM [1]
(Cell-free assay)
12.9 nM
体外試験

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPJXHhJUUN3ME2zMlI4OzV{IN88US=> MkPBV2FPT0WU
HuO-3N1 MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTRwMUexOFIh|ryP NHf0bnJUSU6JRWK=
LAMA-84 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrY[VdKSzVyPUSuOVg1PjVizszN NUPaZXNYW0GQR1XS
CAL-72 NYPINJp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[wTWM2OD13LkS4NFg1KM7:TR?= NGrkNoRUSU6JRWK=
LoVo NEPrblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn30TWM2OD14LkmzNlM6KM7:TR?= MUHTRW5ITVJ?
HH NIfDUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRThwMke2O|Eh|ryP NXLpNm5JW0GQR1XS
SK-MEL-3 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRThwMki1O|Uh|ryP NHKxNVlUSU6JRWK=
KM12 NYnCWYJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rITGlEPTB;OT6yNVE1OiEQvF2= NYnaT4FUW0GQR1XS
NCI-H1437 MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O3WWlEPTB;OT64NFk4KM7:TR?= NXrLTHRQW0GQR1XS
NCI-H1838 NHLofGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DsTmlEPTB;MUGuNVg3PSEQvF2= M2[2R3NCVkeHUh?=
J-RT3-T3-5 NX;UV|JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFzLkK0NVch|ryP Mm\zV2FPT0WU
GOTO MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;HRZBnUUN3ME2xNU43QTl4IN88US=> NW\RNlBTW0GQR1XS
LB2241-RCC NInqXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjsOXhGUUN3ME2xNU44OTh4IN88US=> NWC2dGFKW0GQR1XS
ES7 NYDLVVU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFzLke4PEDPxE1? MmGxV2FPT0WU
KP-N-YS NXnITpJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L1dGlEPTB;MUKuOlM2PCEQvF2= MYfTRW5ITVJ?
CAL-12T NX7jOnlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LTcGlEPTB;MUOuOlE4KM7:TR?= MoD2V2FPT0WU
COLO-684 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\Ee2lEPTB;MUSuNVU3QSEQvF2= NWTDeIk4W0GQR1XS
DOK MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF3LkOzNlkh|ryP NUnzV3Z3W0GQR1XS
Hs-578-T NXTjdo5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\LTI5KSzVyPUG1MlQyQDJizszN M1rIdnNCVkeHUh?=
D-423MG MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPsdphKSzVyPUG1MlUzOzZizszN MmnQV2FPT0WU
DBTRG-05MG NXLDUJpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DtWmlEPTB;MUWuOlEyOSEQvF2= MUXTRW5ITVJ?
VM-CUB-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fwWWlEPTB;MUWuPVg1QSEQvF2= NXrnT4s{W0GQR1XS
KG-1 MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TGWGlEPTB;MU[uNFk6PiEQvF2= MkK4V2FPT0WU
8305C MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHOTWM2OD1zNj6xPFg6KM7:TR?= MYjTRW5ITVJ?
HuH-7 NES1do9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2foXWlEPTB;MU[uNlY4PCEQvF2= M33ab3NCVkeHUh?=
LXF-289 MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojSTWM2OD1zNj6yO|Q4KM7:TR?= M2Da[3NCVkeHUh?=
NCI-H1793 NXnQV4huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;EZmlEPTB;MU[uOFcyOiEQvF2= MUjTRW5ITVJ?
ChaGo-K-1 NVvZZVJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXHTWM2OD1zNj62OVY5KM7:TR?= NULtVWt3W0GQR1XS
GCIY NGrWVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L3emlEPTB;MU[uO|kxPSEQvF2= NGjnc|ZUSU6JRWK=
SK-MEL-28 MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\Q[mlEPTB;MUeuNFQ4PSEQvF2= NYraPItGW0GQR1XS
NCI-SNU-1 NVr6bIx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXS[otKSzVyPUG3MlEzPjlizszN M{W3enNCVkeHUh?=
CTB-1 NUXmd4FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLKfIFnUUN3ME2xO{4zOjV7IN88US=> NWjMdJUyW0GQR1XS
NCI-H82 M4XjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlX0TWM2OD1zNz60OVc{KM7:TR?= M1\6Z3NCVkeHUh?=
HCC2998 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF5Lk[3N|Mh|ryP MVvTRW5ITVJ?
NCI-H2030 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\1V2lEPTB;MUiuNVk6PyEQvF2= M2nre3NCVkeHUh?=
HuP-T3 NHryVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF6LkW4PFgh|ryP M2\hc3NCVkeHUh?=
697 M2XxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHK5TWJKSzVyPUG5MlAzODFizszN MVfTRW5ITVJ?
MLMA MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIm3XYhKSzVyPUG5MlA2PTdizszN M2q4T3NCVkeHUh?=
HCC70 M2H1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF7LkS4PUDPxE1? NXn4V4RzW0GQR1XS
A704 NVW5OZN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG1TWM2OD1zOT64N|A2KM7:TR?= MY\TRW5ITVJ?
D-283MED M3LwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS2bZVKSzVyPUKwMlU{OzlizszN MnX6V2FPT0WU
U031 NYfQbFdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJzLkG0PFkh|ryP NGC0TJpUSU6JRWK=
HSC-3 NES4[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJzLkG4N|Uh|ryP NH\2dopUSU6JRWK=
JVM-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3znd2lEPTB;MkKuOVA3KM7:TR?= MnTKV2FPT0WU
Mewo NIrNeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH22RnVKSzVyPUKyMlUxPzNizszN MonBV2FPT0WU
YH-13 M2H5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPUOFNmUUN3ME2yNk42OTJ|IN88US=> NHrY[YJUSU6JRWK=
LB1047-RCC M1fnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n3[mlEPTB;MkKuOVg4QSEQvF2= MlP6V2FPT0WU
HCC2157 M{PqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ{LkiwOVQh|ryP NWrMdXBKW0GQR1XS
SNU-449 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXJTWM2OD1{Mj64O|Q5KM7:TR?= NHXtWZlUSU6JRWK=
Ramos-2G6-4C10 NYTLXWpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFviUHNKSzVyPUKyMlk3KM7:TR?= MWPTRW5ITVJ?
CHL-1 NVznR|lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW5TWM2OD1{Mz63NlkzKM7:TR?= NVP3SHZ{W0GQR1XS
SK-MEL-30 NHvIcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTqTWM2OD1{ND60OlYzKM7:TR?= NYC2d|FbW0GQR1XS
PANC-08-13 NILEW|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXBTWM2OD1{NT6wPVM5KM7:TR?= NW\HSpBIW0GQR1XS
QIMR-WIL Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz0eYpuUUN3ME2yOU4yQDV6IN88US=> NFTheZlUSU6JRWK=
BFTC-905 M2r3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJ3LkW5OFQh|ryP NFz5O45USU6JRWK=
GI-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlztTWM2OD1{NT63NFU2KM7:TR?= NX63V|c2W0GQR1XS
MDA-MB-415 NU\MVYFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ4LkWwN|Mh|ryP MmTkV2FPT0WU
GT3TKB M3ewUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTyfIIxUUN3ME2yOk42OzR{IN88US=> M2PUVXNCVkeHUh?=
DEL MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmycVVKUUN3ME2yOk45OzV4IN88US=> MVLTRW5ITVJ?
KOSC-2 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf6ZYhEUUN3ME2yOk46ODd3IN88US=> MnPUV2FPT0WU
RVH-421 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS0V4ZDUUN3ME2yO{4zQTJzIN88US=> Ml35V2FPT0WU
EW-13 NWLrUm94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjqN2JKSzVyPUK3MlQ{ODhizszN MUDTRW5ITVJ?
639-V MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf6VIFYUUN3ME2yO{42OTF7IN88US=> MWHTRW5ITVJ?
A2780 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrVb3N7UUN3ME2yO{43PDFizszN NHj6UWpUSU6JRWK=
SW982 Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfYemk3UUN3ME2yO{46ODV{IN88US=> M13pTnNCVkeHUh?=
SW1710 M1u3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nNPGlEPTB;MkiuNFk5OSEQvF2= NXrZS|NxW0GQR1XS
HCC1569 MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ToT2lEPTB;MkiuOFg6PyEQvF2= MlfhV2FPT0WU
MV-4-11 Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ6LkW3N|Uh|ryP NUTv[YtkW0GQR1XS
BHT-101 MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJ6Lk[1O|Ih|ryP MWHTRW5ITVJ?
Ca9-22 Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnjbYdKSzVyPUK4MlcyPCEQvF2= MXfTRW5ITVJ?
HAL-01 M{ixVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH4WG5KSzVyPUK4Mlc3OTVizszN NUDyepR4W0GQR1XS
D-263MG NHTTdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFToTlRKSzVyPUK5MlM1PCEQvF2= MVjTRW5ITVJ?
NEC8 NGHkO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2wNlNlUUN3ME2yPU42PTR6IN88US=> Mn;sV2FPT0WU
EKVX NY\vfFNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;pTHZ6UUN3ME2zNU42QDR5IN88US=> MkHwV2FPT0WU
EM-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULKfXYxUUN3ME2zNU43OzB2IN88US=> NYe1Wol{W0GQR1XS
MFM-223 NWjjd3B5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu5Z3FlUUN3ME2zNU45ODl6IN88US=> Mm[yV2FPT0WU
SK-PN-DW MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT6SoJKSzVyPUOyMlE1ODZizszN NGfxSmxUSU6JRWK=
HuO9 M3faUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvqTWM2OD1|Mj61NlgzKM7:TR?= MXjTRW5ITVJ?
MHH-PREB-1 NY\IdZZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTjTWM2OD1|Mj62NlM1KM7:TR?= M1HkdHNCVkeHUh?=
OVCAR-4 NHe2dIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm0fnFTUUN3ME2zNk45OzZ|IN88US=> MX7TRW5ITVJ?
NCI-H1648 NFLyVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\QfGdQUUN3ME2zNk45PjVzIN88US=> NV\F[HR4W0GQR1XS
MKN1 M3ez[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPCOodKSzVyPUO0MlEyODFizszN NVv5S|hGW0GQR1XS
KYSE-450 NWfPU5ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTsWYVOUUN3ME2zOE43PDR2IN88US=> MlK5V2FPT0WU
ES8 Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDzdG9KSzVyPUO0Mlg6PzVizszN MmntV2FPT0WU
MS-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr2TWM2OD1|ND65OVU1KM7:TR?= NIXtWFhUSU6JRWK=
HOP-92 M{PVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzjdI9KSzVyPUO1MlkzPzdizszN NV3XR4cxW0GQR1XS
SKG-IIIa M4HhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN4LkK1OlEh|ryP M1HIUHNCVkeHUh?=
TE-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDvTWM2OD1|Nj61NlQ{KM7:TR?= MUDTRW5ITVJ?
SK-NEP-1 NYrweI1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\mTWM2OD1|Nz62O|Q1KM7:TR?= NYjSPHl{W0GQR1XS
DB NILzW|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHSOoc1UUN3ME2zO{46OTh3IN88US=> M3PIN3NCVkeHUh?=
IA-LM NYL5ZoNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTN6LkCyN|kh|ryP M2jpenNCVkeHUh?=
COLO-829 M17hcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fUOGlEPTB;M{iuOFE2QSEQvF2= MUnTRW5ITVJ?
TGBC11TKB NVH6UZJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfLNJNjUUN3ME2zPU4yPDB6IN88US=> MYPTRW5ITVJ?
CAL-51 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDNTWM2OD12MD6wOlEzKM7:TR?= NYmzSWNQW0GQR1XS
NCI-H2228 NVHBNYtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDRfphGUUN3ME20NE4{PjZ{IN88US=> M4\hRnNCVkeHUh?=
C32 NEHrOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELmcVJKSzVyPUSwMlQxOjRizszN MV;TRW5ITVJ?
KU-19-19 NUD5[pg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXH2SlRGUUN3ME20NE44Pjh|IN88US=> NHn4SHFUSU6JRWK=
KNS-62 NHnNRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTBTWM2OD12MD64N|gyKM7:TR?= NX36eGZ2W0GQR1XS
FADU NYrNSIdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTRzLkK1NFIh|ryP NFLXNY1USU6JRWK=
CAL-33 NWjTSnBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDyUFR2UUN3ME20Nk43PzR7IN88US=> NFzsc4hUSU6JRWK=
CHP-134 NGTlTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jhcWlEPTB;NEKuPFQ6PiEQvF2= M{DjRXNCVkeHUh?=
HDLM-2 NIr3eHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3nTWM2OD12Mj65NFg1KM7:TR?= Mli4V2FPT0WU
NBsusSR MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPQOJliUUN3ME20N{4xPzJ3IN88US=> NHv0XHVUSU6JRWK=
SW954 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTR|LkGwOVMh|ryP NH3kPIpUSU6JRWK=
HCC1806 NXzJVoF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTR|LkSxNUDPxE1? NUTTR3B6W0GQR1XS
VMRC-RCZ MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTR|LkS1PFYh|ryP MVTTRW5ITVJ?
A549 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LqTGlEPTB;NEOuPVMyKM7:TR?= Mn3PV2FPT0WU
NKM-1 NFrJNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTR|Lkm1OVgh|ryP MUTTRW5ITVJ?
DMS-273 NGrVOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{njTGlEPTB;NESuO|U3PyEQvF2= M1yyPXNCVkeHUh?=
TYK-nu NWXrTopTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37NNGlEPTB;NEWuNVI{PCEQvF2= MYLTRW5ITVJ?
KALS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3J[Ip1UUN3ME20OU4yPDZizszN NFTjcnpUSU6JRWK=
A101D M3XZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELwRnlKSzVyPUS1MlQ1PTZizszN M{X3XXNCVkeHUh?=
G-361 M1HQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP1TWM2OD12Nj6yNVM5KM7:TR?= M2PNWXNCVkeHUh?=
KARPAS-299 MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjTfXhnUUN3ME20Ok4{PTF4IN88US=> M4\xTnNCVkeHUh?=
RS4-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP0NVFKSzVyPUS2MlU1OiEQvF2= NHS3dmdUSU6JRWK=
HT-1376 NXu1Z2M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTR4Lke0NlYh|ryP MV7TRW5ITVJ?
SK-N-AS MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX2xTWI{UUN3ME20Ok44QDJ{IN88US=> MlfUV2FPT0WU
MG-63 NE\FZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDXTWM2OD12Nj65NFM3KM7:TR?= NY[3NmVYW0GQR1XS
EPLC-272H NECwZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvrVppKSzVyPUS2Mlk2ODNizszN MXfTRW5ITVJ?
BALL-1 NHrlb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLkTWM2OD12Nz64N|Ih|ryP MnnJV2FPT0WU
LCLC-97TM1 Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DhOWlEPTB;NEiuNlAzKM7:TR?= NVjRZ4hJW0GQR1XS
HO-1-N-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDWO5BrUUN3ME20PE46Pjd4IN88US=> MYTTRW5ITVJ?
MFE-280 NVnFcZBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTR7LkS2NVch|ryP M4js[nNCVkeHUh?=
NCI-H526 NH[zTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV31WXpCUUN3ME20PU45OTZ|IN88US=> NVLCNZI4W0GQR1XS
D-566MG M1\nTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PRV2lEPTB;NEmuPVA6PiEQvF2= NH3BW3RUSU6JRWK=
BB30-HNC NI\WfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfjXVBKSzVyPUS5Mlk1QThizszN NHT0O2lUSU6JRWK=
SK-N-DZ MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkflTWM2OD13MD6wOFgyKM7:TR?= MX;TRW5ITVJ?
HepG2  M2LXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C4TVExyqEQvF2= M{H0NFI1KGh? MoG2Zoxw[2u|IGPDMWlKUTNvaX7keYNm\CCVIIDoZZNmKGG{cnXzeC=> NELtXZMzPTV{N{GyNy=>
HepG2  NFGyZo5HfW6ldHnvckBCe3OjeR?= Mof0NVDDqM7:TR?= M2jZSlI1KGh? M2XFW5N2eHC{ZYPz[ZMhfGinIIDoc5NxcG:{eXzheIlwdnNib3[gRXROKG:wIGPldlE6QDFuIFPob|Ehd25iU3XyN|Q2NCCFaHuyJI9vKFSqck[4MEBidmRiQ3TrNkBwdiCWeYKxOUBqdmS3Y3XkJIJ6KFOFLVnJTVM> MV[yOVUzPzF{Mx?=
KATO III  NGC4[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrXS|YzNjVxNT:3MlUh|ryP MV3EUXNQ M{LSdoVvcGGwY3XzJJRp\SC2b4jpZ4l1gSCxZjDvcIFx[XKrYh?= MmnHNlQ5PDF5MUi=
hTCEpi NX;1UXNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDyVlAyOCEQvF2= Mn3OSG1UVw>? NI\teVFxemW4ZX70d{B1cGViY4n0c5BifGirYzDl[oZm[3Rib3[gTHNXNTF? NVHxN2hVOjR|N{C4N|U>
MCF10A NYLTfZZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSxNEDPxE1? NH3qT2szPCCq MWXEUXNQ NH;CVIhxd3SnboTpZZRmeyC2aHWgZ5l1d3SxeHnjbZR6KG:oIFfB NGLmXW0zPDF3MEW5OS=>
HL-60  MnHTSpVv[3Srb36gRZN{[Xl? MUOxNEDPxE1? MlHwNE42KGh? NIL2c5JFVVOR MnzTdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gR4hsOsLi M{\VeFI{QTN2NEGx
MCF-7 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:3bnpVOS1zMEFOwG0> MkXtNlQhcA>? NXrpcYpPTkKV NHvv[JFqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w Mnn4NlMyQDV|NEe=
HeLa  MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnyNU0yODEQvF2= NGTVRWczPCCq MU\GRnM> MomxbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? MkTkNlMyQDV|NEe=
SH-SY5Y NV;vdZhFTnWwY4Tpc44hSXO|YYm= NF7Ve|kyOMLizszNxsA> M2noUlI1KGh? M3fqfolvcGmkaYTzJINtcW:zdXnuc4wucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDV| NGi2ZXozOjZ{N{K5OC=>
IMR-32 MnPISpVv[3Srb36gRZN{[Xl? MnS0NVDDqM7:TdMg M1[0XVI1KGh? NX\rRXlucW6qaXLpeJMh[2yrb4H1bY5wdC2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCyNUO= NIjMWJozOjZ{N{K5OC=>
A549 MX;GeY5kfGmxbjDBd5NigQ>? MnHqNVDDqM7:TdMg NF7ZS4cyKGh? M3HMRZN2eHC{ZYPz[ZMhVmGwbz3Dc{1qdmS3Y3XkJJA2OyCjY3P1cZVt[XSrb36= NXvhTo5NOjJ3NUmzNlE>
T47D  NFT2TYJHfW6ldHnvckBCe3OjeR?= NIHudJUzOMLibV2= MoHsNlQhcA>? MVLEUXNQ NVzLU4FJeHKndnXueJMhUVJvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBK|rqEzsG= M3XPTlIyOTR2OEC1
A29 MEF NFrOeIhHfW6ldHnvckBCe3OjeR?= NHvreFQyOMLizszNxsA> MU[xbC=> M4raT4Jtd2Otc9MgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDa4SgZZQhW2W{NEezxsA> NHLjZ28zODB3M{e4NS=>
MDA-MB-453  NX3v[od[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XjRVUuPDBizszN MnzLO|IhcA>? M1jKUmlEPTBib3[gNVAh|ryP M2jSWFIxODV|N{ix
PC-3 NG\H[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXDOU01OCEQvF2= MmDvO|IhcA>? NWTn[ZpnUUN3MDDv[kAyOCEQvF2= MVOyNFA2Ozd6MR?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
細胞試験:

[1]

+ 展開
  • 細胞株: U2OS cells
  • 濃度: 10 μM
  • 反応時間: 2 hours
  • 実験の流れ:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: BALB/c nu/nu nude mice bearing LU1205 cells
  • 製剤: --
  • 投薬量: 10 μM
  • 投与方法: --
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO and 47.5% PEG300
混合させたのち直ちに使用することを推奨します。
10 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 395.49
化学式

C21H17NO3S2

CAS No. 587871-26-9
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

ATM/ATRシグナル伝達経路

ATM/ATR Inhibitors with Unique Features

相関ATM/ATR製品

Tags: KU-55933 (ATM Kinase Inhibitor)を買う | KU-55933 (ATM Kinase Inhibitor) ic50 | KU-55933 (ATM Kinase Inhibitor)供給者 | KU-55933 (ATM Kinase Inhibitor)を購入する | KU-55933 (ATM Kinase Inhibitor)費用 | KU-55933 (ATM Kinase Inhibitor)生産者 | オーダーKU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor)化学構造 | KU-55933 (ATM Kinase Inhibitor)分子量 | KU-55933 (ATM Kinase Inhibitor)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID